Retatrutide, developed by Soma, represents a promising breakthrough in metabolic control . This unique medication combines incretin receptor agonist properties with gut-derived pathway activation , indicating impressive efficacy in clinical studies for body loss . Researchers believe the drug may represent a alternative solution for patients strugg